Baker Bros. Advisors LP Acquires Celcuity Inc. Common Stock

Summary

Baker Bros. Advisors LP, along with other beneficial owners, has reported the acquisition of common shares in Celcuity Inc. Celcuity Inc. published the original content via EDGAR on September 10, 2025.Reuters

Impact Analysis

So basically, Baker Bros. Advisors LP is doubling down on Celcuity Inc. right after the FDA accepted its New Drug Application for gedatolisib, which targets HR+/HER2- advanced breast cancer.MSN This move is a strong vote of confidence, especially as Celcuity has just expanded its credit facility to $500 million to support FDA submissions and commercial launch preparations.Tip Ranks+ 2 The timing suggests Baker Bros. sees significant upside potential, possibly linked to the FDA’s Real-Time Oncology Review program, which could expedite drug approval.MSN The market might be underestimating the impact of this acquisition, given Celcuity’s current neutral stock rating and financial challenges.Tip Ranks With a strong buy consensus and price target upside, this could be a strategic entry point for investors looking to capitalize on Celcuity’s growth trajectory in oncology therapies.Tip Ranks